孤儿受体
前列腺癌
受体
癌症研究
癌症
G蛋白偶联受体
生物
核受体
雌激素受体
细胞生长
雄激素受体
前列腺
医学
内科学
乳腺癌
转录因子
遗传学
基因
出处
期刊:The Prostate
[Wiley]
日期:2022-05-10
卷期号:82 (10): 1016-1024
被引量:4
摘要
Abstract Background The identification of new cellular receptors has been increasing rapidly. A receptor is called “orphan” if an endogenous ligand has not been identified yet. Methods Here we review receptors that contribute to prostate cancer and are considered orphan or partially orphan. This means that the full spectrum of their endogenous ligands remains unknown. Results The orphan receptors are divided into two major families. The first group includes G protein‐coupled receptors. Most are orphan olfactory receptors. OR51E1 inhibits cell proliferation and induces senescence in prostate cancer. OR51E2 inhibits prostate cancer growth, but promotes invasiveness and metastasis. GPR158, GPR110, and GPCR‐X play significant roles in prostate cancer development and progression. However, GPR160 induces cell cycle arrest and apoptosis. The other major subset of orphan receptors are nuclear receptors. Receptor‐related orphan receptor α (RORα) inhibits tumor growth, but RORγ stimulates androgen receptor signaling. PXR contributes to metabolic deactivation of androgens and inhibits cell proliferation. TLX has protumorigenic effects in prostate cancer, while its knockdown triggers cellular senescence and growth arrest. Estrogen‐related receptor ERRγ can inhibit tumor growth but ERRα is protumorigenic. Dax1 and short heterodimeric partner are also inhibitory in prostate cancer. Conclusion There is a “zoo” of relatively underappreciated orphan receptors that play key roles in prostate cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI